AI Engines For more Details: Perplexity Kagi Labs You
Athlete's Foot (Tinea Pedis): Sertaconazole nitrate effectively treats athlete's foot, a common fungal infection that affects the skin between the toes and on the soles of the feet. It relieves symptoms such as itching, burning, redness, and scaling associated with this condition.
Jock Itch (Tinea Cruris): Sertaconazole nitrate is also effective in treating jock itch, a fungal infection that affects the groin area, inner thighs, and buttocks. It helps alleviate symptoms such as itching, redness, and rash in the affected areas.
Ringworm (Tinea Corporis): Ringworm is a fungal infection that can affect various parts of the body, including the trunk, limbs, and face. Sertaconazole nitrate is used to treat ringworm infections by targeting the fungus responsible for the condition and relieving associated symptoms such as itching and skin irritation.
Yeast Infections: Sertaconazole nitrate is sometimes prescribed to treat yeast infections of the skin, particularly those caused by Candida species. It helps reduce symptoms such as itching, redness, and inflammation associated with these infections.
Topical Application: Sertaconazole nitrate is typically applied topically to the affected area of the skin in the form of a cream or gel. It should be applied as directed by a healthcare professional, usually once or twice daily, for the prescribed duration of treatment.
Antifungal Activity: Sertaconazole nitrate exerts its antifungal activity by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes. By disrupting fungal cell membrane integrity, it effectively kills or inhibits the growth of the fungus causing the infection.
Broad Spectrum: Sertaconazole nitrate exhibits broad-spectrum antifungal activity against a variety of fungal species, including dermatophytes (e.g., Trichophyton, Microsporum), yeasts (e.g., Candida), and certain molds.
Safety Profile: Sertaconazole nitrate is generally well-tolerated when used as directed. However, like all medications, it may cause side effects in some individuals, such as mild skin irritation, burning, stinging, or itching at the site of application. Serious allergic reactions are rare but possible.
Consultation: Before using sertaconazole nitrate, individuals should consult with a healthcare professional, especially if they have a history of sensitivity to antifungal medications or other skin sensitivities.
Compliance: It is important for individuals to use sertaconazole nitrate as prescribed and complete the full course of treatment, even if symptoms improve before the end of the treatment period, to ensure the complete eradication of the fungal infection and prevent recurrence.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 2.6 | 1 | 1.6 |
| Age-Related Macular Degeneration and Glaucoma | 1 | 0.4 | 1.5 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 2.2 | |
| Allergies | 4.9 | 2.6 | 0.88 |
| Allergy to milk products | 1.3 | 0.4 | 2.25 |
| Alopecia (Hair Loss) | 2.4 | 2.4 | |
| Alzheimer's disease | 2.7 | 7.7 | -1.85 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3 | 0.6 | 4 |
| Ankylosing spondylitis | 3.4 | 2.3 | 0.48 |
| Anorexia Nervosa | 0.4 | 3.3 | -7.25 |
| Antiphospholipid syndrome (APS) | 1.7 | 1.7 | |
| Asthma | 1.5 | 0.9 | 0.67 |
| Atherosclerosis | 1 | 2 | -1 |
| Atrial fibrillation | 3.7 | 1.7 | 1.18 |
| Autism | 11.2 | 9.2 | 0.22 |
| Bipolar Disorder | 1.2 | 2 | -0.67 |
| Brain Trauma | 0.5 | 0.8 | -0.6 |
| Carcinoma | 3.2 | 2.7 | 0.19 |
| Celiac Disease | 1.3 | 2.7 | -1.08 |
| Cerebral Palsy | 0.5 | 1.8 | -2.6 |
| Chronic Fatigue Syndrome | 5.7 | 6.9 | -0.21 |
| Chronic Kidney Disease | 3.2 | 3 | 0.07 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | -1.5 | |
| Chronic Urticaria (Hives) | 0.5 | 2 | -3 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 1.5 | -2.75 |
| Colorectal Cancer | 2.6 | 1 | 1.6 |
| Constipation | 1.8 | 1 | 0.8 |
| Coronary artery disease | 2.5 | 1 | 1.5 |
| COVID-19 | 9.9 | 14.8 | -0.49 |
| Crohn's Disease | 7.3 | 7.1 | 0.03 |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 1 | -1 | |
| Depression | 8.3 | 8.6 | -0.04 |
| Eczema | 1 | 1.4 | -0.4 |
| Endometriosis | 2.2 | 1 | 1.2 |
| Epilepsy | 2.2 | 2 | 0.1 |
| Fibromyalgia | 4.1 | 3.4 | 0.21 |
| Functional constipation / chronic idiopathic constipation | 5.1 | 4.7 | 0.09 |
| gallstone disease (gsd) | 2.4 | 0.5 | 3.8 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.9 | 1 | 0.9 |
| Generalized anxiety disorder | 1.5 | 1.3 | 0.15 |
| giant cell arteritis | 0.5 | -0.5 | |
| Gout | 0.5 | -0.5 | |
| Graves' disease | 1.2 | 2 | -0.67 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 2.8 | 0.3 | 8.33 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.3 | 1.5 | 0.53 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.1 | 4 |
| hyperglycemia | 1.3 | -1.3 | |
| Hyperlipidemia (High Blood Fats) | 0.5 | 0.5 | 0 |
| hypersomnia | 0.5 | -0.5 | |
| hypertension (High Blood Pressure | 1.7 | 3.7 | -1.18 |
| Hypothyroidism | 1.5 | -1.5 | |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 4.9 | -4.9 | |
| Inflammatory Bowel Disease | 4.2 | 10.7 | -1.55 |
| Insomnia | 0.8 | 1.3 | -0.63 |
| Intelligence | 1.6 | 1 | 0.6 |
| Intracranial aneurysms | 1.7 | 0.5 | 2.4 |
| Irritable Bowel Syndrome | 2.6 | 3.4 | -0.31 |
| Liver Cirrhosis | 3.7 | 2.8 | 0.32 |
| Long COVID | 8.9 | 9.4 | -0.06 |
| Low bone mineral density | 1.5 | -1.5 | |
| Lung Cancer | 1.6 | -1.6 | |
| ME/CFS with IBS | 1.5 | 3.3 | -1.2 |
| ME/CFS without IBS | 3 | 2.7 | 0.11 |
| Menopause | 0 | 0 | |
| Metabolic Syndrome | 7.6 | 7.3 | 0.04 |
| Mood Disorders | 10.9 | 9.1 | 0.2 |
| multiple chemical sensitivity [MCS] | 0 | 0.5 | 0 |
| Multiple Sclerosis | 3.5 | 8 | -1.29 |
| Multiple system atrophy (MSA) | 1.1 | 1 | 0.1 |
| Neuropathy (all types) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3 | 4.4 | -0.47 |
| Obesity | 9.2 | 3.9 | 1.36 |
| obsessive-compulsive disorder | 6.2 | 5.4 | 0.15 |
| Osteoarthritis | 2.8 | 0.5 | 4.6 |
| Osteoporosis | 1.8 | 0.9 | 1 |
| Parkinson's Disease | 2 | 4.9 | -1.45 |
| Polycystic ovary syndrome | 3.2 | 2 | 0.6 |
| Postural orthostatic tachycardia syndrome | 0.5 | 0.5 | 0 |
| Premenstrual dysphoric disorder | 1 | 0.4 | 1.5 |
| primary biliary cholangitis | 0.5 | 1.1 | -1.2 |
| Psoriasis | 4.4 | 3.6 | 0.22 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.7 | 3.7 | 1.08 |
| Rosacea | 1.5 | 1 | 0.5 |
| Schizophrenia | 5.4 | 2.5 | 1.16 |
| scoliosis | 0.5 | 1.5 | -2 |
| Sjögren syndrome | 1.9 | 2.8 | -0.47 |
| Sleep Apnea | 1.5 | 2.3 | -0.53 |
| Stress / posttraumatic stress disorder | 2.2 | 2.8 | -0.27 |
| Systemic Lupus Erythematosus | 4.1 | 2 | 1.05 |
| Tic Disorder | 1.5 | 2.1 | -0.4 |
| Tourette syndrome | 0 | 0.3 | 0 |
| Type 1 Diabetes | 3.7 | 2.5 | 0.48 |
| Type 2 Diabetes | 8.1 | 7.1 | 0.14 |
| Ulcerative colitis | 2.1 | 4.9 | -1.33 |
| Unhealthy Ageing | 6.6 | 2 | 2.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.